A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study

J. Kellogg Parsons, Peter A. Pinto, Christian P. Pavlovich, Edward Uchio, Hyung L. Kim, Mikel N. Nguyen, James L. Gulley, Christina Jamieson, Chiu-Hsieh Hsu, Margarita Wojtowicz, Howard Parnes, Jeffrey Schlom, William L. Dahut, Ravi A. Madan, Renee N. Donahue, Hsiao-Hui Chow

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

The Immunotherapy to Prevent Progression on Active Surveillance Study is the first trial of immunotherapy for localized prostate cancer. We randomized active surveillance patients to PSA-TRICOM (PROSTVAC) or placebo for 5 mo. Final results will be available in 2019.

Original languageEnglish (US)
JournalEuropean Urology Focus
DOIs
StateAccepted/In press - Jan 1 2018

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study'. Together they form a unique fingerprint.

  • Cite this

    Parsons, J. K., Pinto, P. A., Pavlovich, C. P., Uchio, E., Kim, H. L., Nguyen, M. N., Gulley, J. L., Jamieson, C., Hsu, C-H., Wojtowicz, M., Parnes, H., Schlom, J., Dahut, W. L., Madan, R. A., Donahue, R. N., & Chow, H-H. (Accepted/In press). A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study. European Urology Focus. https://doi.org/10.1016/j.euf.2018.08.016